QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)

Enanta Pharmaceuticals (ENTA) Stock Forecast & Price Target

→ Clear Buy, Sell, or Hold Recommendation on any Stock, FREE (From Vector Vest) (Ad)
Free ENTA Stock Alerts
$12.36
+0.10 (+0.82%)
(As of 02/8/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Enanta Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 8 Analyst Ratings

Analysts' Consensus Price Target

$31.50
154.85% Upside
High Forecast$87.00
Average Forecast$31.50
Low Forecast$11.00
TypeCurrent Forecast
2/8/23 to 2/8/24		1 Month Ago
1/9/23 to 1/9/24		3 Months Ago
11/10/22 to 11/10/23		1 Year Ago
2/8/22 to 2/8/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
5 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$31.50$31.88$35.00$68.60
Predicted Upside154.85% Upside39.15% Upside39.58% Upside35.62% Upside
Get Enanta Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

ENTA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ENTA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Enanta Pharmaceuticals Stock vs. The Competition

TypeEnanta PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.67
2.48
Consensus RatingHoldModerate BuyHold
Predicted Upside155.61% Upside938.37% Upside9.06% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/8/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetUnderweight ➝ Underweight$12.00 ➝ $11.00-11.00%
11/22/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetMarket Perform ➝ Market Perform$25.00 ➝ $21.00+128.76%
11/21/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$42.00 ➝ $23.00+157.27%
11/21/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$30.00 ➝ $28.00+213.20%
10/2/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetSector Perform ➝ Sector Perform$25.00 ➝ $15.00+34.29%
8/8/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$49.00 ➝ $18.00-6.93%
2/9/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Perform$49.00-6.95%
2/8/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight$87.00+59.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:55 PM ET.












ENTA Price Target - Frequently Asked Questions

What is Enanta Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Enanta Pharmaceuticals stock is Hold based on the current 1 sell rating, 4 hold ratings and 3 buy ratings for ENTA. The average twelve-month price prediction for Enanta Pharmaceuticals is $31.50 with a high price target of $87.00 and a low price target of $11.00. Learn more on ENTA's analyst rating history.

Do Wall Street analysts like Enanta Pharmaceuticals more than its competitors?

Analysts like Enanta Pharmaceuticals less than other Medical companies. The consensus rating for Enanta Pharmaceuticals is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how ENTA compares to other companies.

Does Enanta Pharmaceuticals's stock price have much upside?

According to analysts, Enanta Pharmaceuticals's stock has a predicted upside of 42.29% based on their 12-month stock forecasts.

What analysts cover Enanta Pharmaceuticals?

Enanta Pharmaceuticals has been rated by HC Wainwright, JMP Securities, JPMorgan Chase & Co., and Oppenheimer in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ENTA) was last updated on 2/8/2024 by MarketBeat.com Staff

From Our Partners
Top Analyst Exposes Imminent Crisis Hurtling Towards America
Porter and Company
Elon Musk's "Project Dojo" is a Game-Changer
Stansberry Research
These cryptos could skyrocket by January
Weiss Ratings
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move
The Oxford Club
The World's First "$20 Trillion Drug
Behind the Markets
All the trading advice you’ve ever received boils down to this
DTI
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse
Legacy Research
Stop buying AI stocks!
Investor Place Media

My Account -